DalCor Pharmaceuticals Canada
Latest round
- Series D
Last raised
- Sep 2023
Total raised
- $180M
Investors
- 7
About DalCor Pharmaceuticals Canada
DalCor Pharmaceuticals Canada Inc.DalCor Pharmaceuticals Canada Inc. specializes in the development of pharmacogenetic treatments for cardiovascular diseases.DalCor Pharmaceuticals is primarily focused on the development and commercialization of dalcetrapib, a pharmacogenetic precision medicine designed to address cardiovascular disease, particularly for individuals with the AA genotype at the rs1967309 location in the ADCY9 gene. This product aims to reduce the incidence of fatal and non-fatal myocardial infarctions (MI) in patients who have experienced acute coronary syndrome (ACS). Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 (DAL-302) Phase 3 trial, which involves 2,000 patients and follows promising results from the earlier dal-GenE study. The company also collaborates with Roche Molecular Systems to provide a companion diagnostic test that identifies suitable candidates for dalcetrapib treatment based on their genetic makeup.DalCor Pharmaceuticals operates with a revenue model primarily based on partnerships and collaborations regarding its flagship product, dalcetrapib. The company holds exclusive worldwide rights for the development, manufacture, and commercialization of this product, positioning it to generate revenue through sales once it receives regulatory approval. Transactions in this business typically involve B2B arrangements with healthcare providers and institutions administering the treatment to eligible patients identified through the diagnostic test.In September 2023, DalCor Pharmaceuticals Canada Inc. The company is focused on advancing the development of dalcetrapib and is aiming to expand its market presence into regions with high prevalence of the AA genotype by 2024.
Who invested in DalCor Pharmaceuticals Canada
7 investors across 2 rounds
See all investors in DalCor Pharmaceuticals Canada
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about DalCor Pharmaceuticals Canada
Who invested in DalCor Pharmaceuticals Canada?
DalCor Pharmaceuticals Canada has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DalCor Pharmaceuticals Canada raised?
DalCor Pharmaceuticals Canada has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did DalCor Pharmaceuticals Canada last raise money?
DalCor Pharmaceuticals Canada's most recent round on record is a Series D, in Sep 2023.
What does DalCor Pharmaceuticals Canada do?
DalCor Pharmaceuticals Canada Inc.
Where is DalCor Pharmaceuticals Canada headquartered?
DalCor Pharmaceuticals Canada is headquartered in Montreal, Canada.
Which VCs invest in companies like DalCor Pharmaceuticals Canada?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at DalCor Pharmaceuticals Canada's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like DalCor Pharmaceuticals Canada? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.